STOCK TITAN

Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Protalix BioTherapeutics (PLX) has scheduled the release of its third quarter 2024 financial results and business update for November 14, 2024. The company will host a conference call and webcast at 8:30 a.m. EST to discuss financial results and provide updates on corporate and regulatory developments. The event will be accessible via toll-free numbers for domestic and international callers, with a Call me™ feature available for immediate connection. A two-week replay will be available on the company's website.

Protalix BioTherapeutics (PLX) ha programmato la pubblicazione dei risultati finanziari del terzo trimestre 2024 e dell'aggiornamento aziendale per il 14 novembre 2024. L'azienda organizzerà una conference call e un webcast alle 8:30 a.m. EST per discutere i risultati finanziari e fornire aggiornamenti sugli sviluppi aziendali e normativi. L'evento sarà accessibile tramite numeri verdi sia per i chiamanti nazionali che internazionali, con la funzione Call me™ disponibile per una connessione immediata. Una registrazione di due settimane sarà disponibile sul sito web dell'azienda.

Protalix BioTherapeutics (PLX) ha programado la publicación de sus resultados financieros del tercer trimestre de 2024 y una actualización empresarial para el 14 de noviembre de 2024. La compañía llevará a cabo una conferencia telefónica y una transmisión por webcast a las 8:30 a.m. EST para discutir los resultados financieros y proporcionar actualizaciones sobre los desarrollos corporativos y regulatorios. El evento será accesible a través de números gratuitos para llamantes nacionales e internacionales, con una función Call me™ disponible para una conexión inmediata. Una repetición de dos semanas estará disponible en el sitio web de la empresa.

Protalix BioTherapeutics (PLX)는 2024년 11월 14일에 2024년 3분기 재무 결과 및 사업 업데이트 발표를 예정하고 있습니다. 회사는 오전 8시 30분 EST에 재무 결과를 논의하고 기업 및 규제 개발에 대한 업데이트를 제공하기 위해 전화 회의 및 웹캐스트를 개최할 예정입니다. 이 이벤트는 국내 및 국제 전화인을 위한 무료 전화 번호를 통해 접근할 수 있으며, 즉시 연결을 위한 Call me™ 기능도 제공됩니다. 두 주간의 재생은 회사 웹사이트에서 이용할 수 있습니다.

Protalix BioTherapeutics (PLX) a prévu la publication de ses résultats financiers du troisième trimestre 2024 ainsi qu'une mise à jour sur l'activité pour le 14 novembre 2024. L'entreprise organisera une conférence téléphonique et un webcast à 8h30 EST pour discuter des résultats financiers et fournir des mises à jour sur les développements d'entreprise et réglementaires. L'événement sera accessible via des numéros gratuits pour les appelants nationaux et internationaux, avec une fonctionnalité Call me™ disponible pour une connexion immédiate. Une rediffusion de deux semaines sera disponible sur le site web de l'entreprise.

Protalix BioTherapeutics (PLX) hat die Veröffentlichung seiner finanziellen Ergebnisse für das dritte Quartal 2024 und ein Unternehmensupdate für den 14. November 2024 geplant. Das Unternehmen wird um 8:30 Uhr EST eine Telefonkonferenz und einen Webcast abhalten, um die finanziellen Ergebnisse zu besprechen und Updates zu Unternehmens- und regulatorischen Entwicklungen zu geben. Die Veranstaltung wird über gebührenfreie Nummern für inländische und internationale Teilnehmer zugänglich sein, wobei eine Call me™-Funktion für eine sofortige Verbindung verfügbar ist. Eine zweiwöchige Wiederholung wird auf der Website des Unternehmens verfügbar sein.

Positive
  • None.
Negative
  • None.

Company to host conference call and webcast at 8:30 a.m. EST

CARMIEL, Israel, Nov. 7, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended September 30, 2024 and provide a business and clinical update on November 14, 2024.

Protalix Biotherapeutics Logo

Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments.

Conference Call Details:
Date:                           Thursday, November 14, 2024
Time:                           8:30 a.m. Eastern Standard Time (EST)
Toll Free:                    1-877-423-9813
International:             1-201-689-8573
Israeli Toll Free:         1-809-406-247
Conference ID:          13749493
Call me™:                   https://tinyurl.com/2n9fhumh

The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.

Webcast Details:
Company Link:  https://ir.protalix.com/news-events/events
Webcast Link:    https://tinyurl.com/3be68pkw
Conference ID:  13749493

Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.

About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio®, was approved by both the FDA and the European Medicines Agency in May 2023.

Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others.

Logo - https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg 

Investor Contact
Mike Moyer, Managing Director
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com 

Cision View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-third-quarter-2024-financial-and-business-results-on-november-14-2024-302298569.html

SOURCE Protalix BioTherapeutics, Inc.

FAQ

When will Protalix BioTherapeutics (PLX) release its Q3 2024 earnings?

Protalix BioTherapeutics will release its Q3 2024 financial results on November 14, 2024.

What time is Protalix BioTherapeutics (PLX) Q3 2024 earnings call?

The earnings conference call and webcast will be held at 8:30 a.m. EST on November 14, 2024.

How can I access Protalix BioTherapeutics (PLX) Q3 2024 earnings call?

You can access the call through toll-free numbers (1-877-423-9813 for US), international numbers, or the webcast link available on the company's investor relations website.

Protalix BioTherapeutics, Inc.

NYSE:PLX

PLX Rankings

PLX Latest News

PLX Stock Data

85.31M
73.54M
14.53%
8.09%
4.21%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
HACKENSACK